ATRA - Atara Biotherapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Atara Biotherapeutics, Inc.

611 Gateway Boulevard
Suite 900
South San Francisco, CA 94080
United States
650-278-8930
http://www.atarabio.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees267

Key Executives

NameTitlePayExercisedYear Born
Dr. Isaac E. CiechanoverPres, CEO & Director879.73kN/A1971
Mr. Joseph NewellExec. VP & Chief Technical Operations OfficerN/AN/A1970
Dr. Derrell D. PorterSr. VP & Global Commercial HeadN/AN/A1971
Mr. Utpal KoppikarChief Financial OfficerN/AN/AN/A
Dr. Christopher M. HaqqExec. VP of R&D & Chief Scientific Officer574.52kN/A1966
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. The company is developing tabelecleucel, an advanced T-cell immunotherapy that is Phase III clinical trials for the treatment of rituximab-refractory epstein-barr virus (EBV) associated post-transplant lymphoproliferative disorder, as well as other EBV associated hematologic and solid tumors, including nasopharyngeal carcinoma. It is also developing ATA188 and autologous ATA190 that are in Phase I clinical trials for the treatment of multiple sclerosis; ATA520, a Phase I clinical trial product to treat Wilms tumor 1; and ATA230, which is Phase II clinical trials for refractory cytomegalovirus. In addition, the company is developing ATA368 that is under preclinical development for HIV and cancers. It has license agreements with Memorial Sloan Kettering Cancer Center and Amgen, Inc.; and license, and research and development collaboration agreement with QIMR Berghofer Medical Research Institute. The company was founded in 2012 and is headquartered in South San Francisco, California.

Corporate Governance

Atara Biotherapeutics, Inc.’s ISS Governance QualityScore as of August 1, 2018 is 10. The pillar scores are Audit: 2; Board: 8; Shareholder Rights: 7; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.